Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own
resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of the trial.
The vaccine, HSPPC - 96, is produced individually for each patient using that patient's own
resected tumor tissue.
Not exact matches
In BCS, it is often difficult for the surgeon to locate and
resect the cancerous
tissue all around the core of the
tumor.
However, access to
tumor from distant disease sites may be feasible, raising the question of which
tissue to study, the primary which is
resected or the distant sites which will need the benefit of systemic therapy.